Research location
Cheadle
United Kingdom
Advertisement
Research activity in Cheadle
United KingdomCureCurrent currently publishes aggregate city-level research activity for this location: 8 trials and 8 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Cheadle
8 linked trials · page 1 of 1A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)NCT07759245 · 2026-08-07 · 1 site observation
RECRUITING
A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightNCT07232719 · 2025-11-17 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityNCT06859268 · 2025-03-05 · 1 site observation
ACTIVE_NOT_RECRUITING
An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in AsthmaNCT01706198 · 2012-11-01 · 1 site observation
COMPLETED
A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)NCT01551758 · 2012-03-13 · 1 site observation
COMPLETED
Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes PatientsNCT00965549 · 2009-07-01 · 1 site observation
COMPLETED
Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 DiabetesNCT00622284 · 2008-02-01 · 1 site observation
COMPLETED
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mgNCT00383929 · 2006-09-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.